JP2005538129A5 - - Google Patents

Download PDF

Info

Publication number
JP2005538129A5
JP2005538129A5 JP2004527183A JP2004527183A JP2005538129A5 JP 2005538129 A5 JP2005538129 A5 JP 2005538129A5 JP 2004527183 A JP2004527183 A JP 2004527183A JP 2004527183 A JP2004527183 A JP 2004527183A JP 2005538129 A5 JP2005538129 A5 JP 2005538129A5
Authority
JP
Japan
Prior art keywords
cpt
capecitabine
topotecan
adriamycin
gemcitabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004527183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005538129A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/003388 external-priority patent/WO2004014386A1/en
Publication of JP2005538129A publication Critical patent/JP2005538129A/ja
Publication of JP2005538129A5 publication Critical patent/JP2005538129A5/ja
Withdrawn legal-status Critical Current

Links

JP2004527183A 2002-08-07 2003-07-28 erbBキナーゼ阻害剤および抗腫瘍療法の治療的組合せ Withdrawn JP2005538129A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40170502P 2002-08-07 2002-08-07
US46224703P 2003-04-11 2003-04-11
PCT/IB2003/003388 WO2004014386A1 (en) 2002-08-07 2003-07-28 Therapeutic combinations of erb b kinase inhibitors and antineoplastic therapies

Publications (2)

Publication Number Publication Date
JP2005538129A JP2005538129A (ja) 2005-12-15
JP2005538129A5 true JP2005538129A5 (enExample) 2006-09-14

Family

ID=31720553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004527183A Withdrawn JP2005538129A (ja) 2002-08-07 2003-07-28 erbBキナーゼ阻害剤および抗腫瘍療法の治療的組合せ

Country Status (17)

Country Link
US (2) US20040067942A1 (enExample)
EP (1) EP1549320A1 (enExample)
JP (1) JP2005538129A (enExample)
CN (1) CN1674908A (enExample)
AR (1) AR040792A1 (enExample)
AU (1) AU2003249450A1 (enExample)
BR (1) BR0313470A (enExample)
CA (1) CA2494270A1 (enExample)
IL (1) IL166423A0 (enExample)
MX (1) MXPA05001430A (enExample)
NO (1) NO20051170L (enExample)
PA (1) PA8578001A1 (enExample)
PE (1) PE20040990A1 (enExample)
PL (1) PL375414A1 (enExample)
RU (1) RU2005102836A (enExample)
TW (1) TW200404532A (enExample)
WO (1) WO2004014386A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US7695731B2 (en) 2004-03-22 2010-04-13 Cordis Corporation Local vascular delivery of etoposide in combination with rapamycin to prevent restenosis following vascular injury
JP4823894B2 (ja) 2004-04-09 2011-11-24 中外製薬株式会社 新規水溶性プロドラッグ
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
WO2005117887A1 (en) * 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
CN1968706A (zh) 2004-06-03 2007-05-23 霍夫曼-拉罗奇有限公司 用顺铂和egfr-抑制剂治疗
EP1761264A1 (en) * 2004-06-03 2007-03-14 F.Hoffmann-La Roche Ag Treatment with irinotecan (cpt-11) and an egfr-inhibitor
CA2569139A1 (en) * 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Lapatinib with letrozole for use in a treatment of breast cancer
TW200744603A (en) * 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
JP2009538317A (ja) * 2006-05-26 2009-11-05 バイエル ヘルスケア リミティド ライアビリティ カンパニー 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
RU2325199C2 (ru) * 2006-06-20 2008-05-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ комбинированного лечения местно-распространенных форм рака шейки матки
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
KR20100102609A (ko) * 2007-11-12 2010-09-24 바이파 사이언스 인코포레이티드 Parp 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법
JP2014514359A (ja) * 2011-05-06 2014-06-19 メリマック ファーマシューティカルズ インコーポレーティッド 抗ErbB3剤を含む併用治療において有毒な薬物相互作用を予防するための方法
WO2021178789A1 (en) * 2020-03-06 2021-09-10 Deciphera Pharmaceuticals, Llc Methods of using rebastinib in the treatment of different cancerous disorders
CN118576601A (zh) * 2020-10-23 2024-09-03 和记黄埔医药(上海)有限公司 一种药物组合产品在制备用于治疗结肠癌的药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287223B1 (en) * 1997-04-11 2001-09-11 Liechty, Ii Victor Jay Dulling prevention for sharp cutting edge of blade-opening arrowhead blades when in a closed in-flight position
US6147107A (en) * 1998-12-20 2000-11-14 Virginia Commonwealth University Specific inhibition of the P42/44 mitogen activated protein (map) kinase cascade sensitizes tumor cells
US6281223B1 (en) * 1999-04-13 2001-08-28 Supergen, Inc. Radioenhanced camptothecin derivative cancer treatments
RU2292904C2 (ru) * 2001-01-09 2007-02-10 Мерк Патент Гмбх Комбинированная терапия, использующая ингибиторы рецептора тирозинкиназы и ингибиторы ангиогенезиса

Similar Documents

Publication Publication Date Title
JP2005538129A5 (enExample)
Carmichael The role of gemcitabine in the treatment of other tumours
RU2008118144A (ru) Комбинации иммуномодулирующих олигоодезоксинуклеотидов и способы их применения
Van Meter et al. Bevacizumab: current updates in treatment
Tomek et al. Chemotherapy for malignant pleural mesothelioma: past results and recent developments
RU2007134571A (ru) Комбинация и способы введения терапевтических средств и комбинированной терапии
JP2004525950A5 (enExample)
JP2010514787A5 (enExample)
JP2017025090A5 (enExample)
RU2011145773A (ru) Ингибиторы 1 киназы контрольной точки клеточного цикла для усиления днк-повреждающих агентов
JP2011522773A5 (enExample)
Grünwald et al. Development of the epidermal growth factor receptor inhibitor Tarceva™(OSI-774)
EP2501385B1 (en) Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent
JP2006504745A5 (enExample)
JP2006500346A5 (enExample)
JP2005511597A5 (enExample)
RU2006122350A (ru) Комбинированная химиотерапия
WO2002102306A3 (en) Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
AR040792A1 (es) Combinaciones terapeuticas de inhibidores de quinasa de erb b y terapias antineoplasicas
JP2006502132A5 (enExample)
PL363967A1 (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
JP2019038796A5 (enExample)
JP2007277240A5 (enExample)
RU2008148597A (ru) Фармацевтические комбинации
JP2014500259A (ja) 血液癌を処置する方法